2023-11-07T12:39:44-06:00 2022-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2022-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2023-11-07 1 Amy Finan 999009999 1 Jie Chen CPA P01049760 7038930300 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z Amy Finan 2175 K Street NW 400 Washington DC 20037 33731409 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 13 13 78 0 0 0 26883038 33467236 0 0 30118 78167 0 0 26913156 33545403 2232992 3127948 0 0 7670433 7783266 0 0 358325 16281894 20371513 26185319 31282727 727837 2262676 18738050 21704675 6518849 7350391 12219201 14354284 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 16826411 Vaccine Research & DevelopmentThe Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to prioritize strong vaccine candidates that lack commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research.Ebola has taken the lives of nearly 14,000 people during the last decade. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Sudan ebolavirus and Marburg virus diseases based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Sudan ebolavirus vaccines 11392054 3127948 Global ImmunizationDespite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin's Global Immunization arm focuses on improving vaccine distribution, increasing uptake, and driving more equitable access to vaccination services. Sabin works on these goals with a multi-layered programmatic approach including: advancing research to understand the social and behavioral drivers for vaccine acceptance and demand; fostering peer to peer collaboration on immunization and building capacity and leadership skills for immunization professionals; coalescing multi-sectoral partners and community leaders and influencers to support the introduction and expansion of new and under-utilized vaccines such as the HPV vaccine; and generating essential epidemiological data to inform immunization policy and implementation decisions for diseases such as typhoid. 28218465 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 34 0 1 78 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL WA X The Organization 2406059555 2175 K Street NW 400 Washington DC 20037 Adegbola Richard Trustee 2.00 X 0 0 0 Baylor Norman Trustee 2.00 X 0 0 0 Commins Holman Wendy Trustee 2.00 X 0 0 0 Djibo Yacine Trustee 2.00 X 0 0 0 Fox Elizabeth Trustee 2.00 X 0 0 0 Hoos Axel Trustee 2.00 X 0 0 0 Libson Jeffrey Trustee, Secretary 2.00 X X 0 0 0 Omer Saad Trustee 2.00 X 0 0 0 Rabinovich Regina Trustee, Chair 2.00 X X 0 0 0 Salisbury David Trustee 2.00 X 0 0 0 Shea Jacqueline Trustee 2.00 X 0 0 0 Suzich JoAnn Trustee 2.00 X 0 0 0 Thoren Peter Trustee,Vice Chair,Treasurer 2.00 X X 0 0 0 Finan Amy CEO 40.00 X 440130 0 29052 DeLeon Kiju CFO 40.00 X 214044 0 18670 Davis Brian CFO 40.00 X 166891 0 14102 Garrett Denise VP, Applied Epidemiology 40.00 X 258426 0 28541 Knobler Stacey VP,Vaccine Innovation & Global Immunization 40.00 X 255479 0 22423 King Thomas VP, Nonclinical 40.00 X 244789 0 38774 Vert-Wong Ekaterina VP, Portfolio & Alliance Management 40.00 X 244347 0 34522 Williams Michelle VP, Operations and HR 40.00 X 241435 0 23122 2065541 0 209206 24 0 1 0 Reithera SRL Via di Castel Romano 100 Rome IT 00128 Bulk drug substance production for Ebola 8167000 Texas Biomedical Research Institute 8715 W Military Dr San Antonio TX 78227 Immunogenicity and efficacy testing for 3328787 Batelle Memorial Institute Dept L 998 Columbus OH 43260 Clinical trial tests for R&D program 1233627 BDO USA LLP One International Place 4th Floor Boston MA 02110 Financial and Quality Management for R&D 1219135 PPD Development 26361 Network Place Chicago IL 60673 Regulatory support services and clinical 397571 15 21463101 12004135 33467236 64893 64893 199280 186006 13274 13274 13274 33545403 0 0 78167 X 1073909 1073909 2054039 2054039 882890 724369 125967 32554 5710335 4790986 705887 213462 77579 44537 30706 2336 661020 379488 261636 19896 451442 264858 170036 16548 132811 124811 8000 21708 21708 17317875 16702901 547357 67617 467388 440304 24279 2805 102913 38696 64046 171 84088 34201 49172 715 268707 268707 550586 492322 58254 10 543859 528069 15790 399187 252600 146587 241223 195456 45767 Dues/subscriptions 129540 62738 65020 1782 Recruitment 61548 3965 57478 105 Miscellaneous 47768 7904 39540 324 Books & publications 2312 2312 31282727 28218465 2705937 358325 2243106 1506086 8663012 7361995 4847484 9587532 4154 89556 310497 506438 1721954 991387 700796 730567 514448 444763 1454553 1201953 0 275785 18738050 21704675 4708737 5814295 1810112 1536096 6518849 7350391 X 2745224 4311941 9473977 10042343 12219201 14354284 18738050 21704675 2262676 -127593 0 X X 0 1 X 1 0 X 10410527 9462400 23177961 26883038 33467236 103401162 10410527 9462400 23177961 26883038 33467236 103401162 40230446 63170716 98272 147130 22343 29272 64893 361910 17077 17077 103780149 0.60870 0.54710 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 161 161 31282566 31282727 1000000 250000 0 0 838024 1000000 1000000 1000000 3838024 5757036 108 161 269 209506 250000 250000 250000 959506 1439259 1192938 626553 566385 529016 364834 164182 730567 Deferred compensation liability 477003 Lease liability - operating lease 1059093 1536096 X 33495428 -127593 77618 -49975 33545403 0 33545403 31360345 77618 77618 31282727 0 31282727 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites, Vaccine Acceptance Small Grants Program awardee 732755 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 161333 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria,Belgium 0 0 Grants to recipients located in region Bulk drug substance production for ebola/marburg, Vaccine Acceptance Small Grants Program awardee 34194 Central America and the Caribbean - Antigua & Barbuda, Aruba, Bahamas, 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 51980 East Asia and the Pacific - Australia, Brunei, Burma, Cambodia, 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 15500 South America 0 0 Grants to recipients located in region Epidemiology study site/Vaccine Acceptance journalist mentoring grant 1058277 0 0 0 0 0 0 2054039 0 2054039 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Epidemiology study site 140219 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Epidemiology study site 341969 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine misinformation intervention module development 11352 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 16878 EFT 0 Central America and the Caribbean - Antigua & Barbuda, Aruba, Bahamas, Vaccine Acceptance Small Grants Program awardee 51980 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Epidemiology study site 184820 EFT 0 East Asia and the Pacific - Australia, Brunei, Burma, Cambodia, Vaccine Acceptance Small Grants Program awardee 13500 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 43449 EFT 0 South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, Epidemiology study site 1027256 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine misinformation intervention module development 7789 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine misinformation intervention module development 7952 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine Acceptance journalist mentoring grant 26235 EFT 0 Europe (Including Iceland & Greenland) Vaccine Acceptance nurse storytelling training grant 34194 EFT 0 South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, Vaccine Acceptance journalist mentoring grant 31020 EFT 0 14 COVID-19 Routine Recovery small grant mentorshipships East Asia and the Pacific 1 2000 EFT Vaccine Acceptance Small Grants Program awardee COVID-19 Routine Recovery small grant mentorshipships Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, 23 106630 EFT COVID-19 Routine Recovery small grant mentorshipships South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, 1 4600 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). Part III Accounting Method: 1 AIDS Vaccine Advocacy Coalition 423 West 127th Street 4th Floor New York NY 10027 943240841 501c3 75452 0 Vaccine Acceptance research site International Women's Media Foundation 1625 K Street NW Suite 1275 Washington DC 20006 521648942 501c3 112500 0 Vaccine Acceptance journalist mentoring grant Johns Hopkins University 12529 Collections Center Drive Chicago IL 60693 520595110 501c3 142297 0 Vaccine Acceptance research site Loma Linda University Cash Concentration 11065 Campus Street Loma Linda CA 92350 951816009 501c3 44267 0 Vaccine Acceptance Small Grants Program awardee Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501c3 145963 0 Epidemiology study site Stanford University Lockbox PO Box 44253 San Francisco CA 94144 941156365 501c3 343715 0 Epidemiology study site The Regents of the University of California 1608 Rhode Island Ave NW Washington DC 20036 943067788 501c3 39930 0 Vaccine Acceptance Small Grants Program awardee The Public Good Projects 401 Park Avenue S10th FL New York NY 10016 462717584 501c3 92200 0 Vaccine misinformation intervention module development Ariadne Labs 75 Francis Street Boston MA 02115 042312909 501c3 77585 0 COVID-19 vaccination Community of Practice development 9 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy CEO 387395 0 50000 0 2735 0 10141 0 18911 0 469182 0 0 0 Garrett Denise VP, Applied Epidemiology 248456 0 7000 0 2970 0 10354 0 18187 0 286967 0 0 0 King Thomas VP, Nonclinical 242947 0 0 0 1842 0 10417 0 28357 0 283563 0 0 0 Vert-Wong Ekaterina VP, Portfolio & Alliance Management 242553 0 0 0 1794 0 9583 0 24939 0 278869 0 0 0 Knobler Stacey VP,Vaccine Innovation & Global Immun 225578 0 28000 0 1901 0 9241 0 13182 0 277902 0 0 0 Williams Michelle VP, Operations and HR 226513 0 13000 0 1922 0 9173 0 13949 0 264557 0 0 0 DeLeon Kiju CFO 211986 0 0 0 2058 0 6786 0 11884 0 232714 0 0 0 Davis Brian CFO 116616 0 50000 0 275 0 3883 0 10219 0 180993 0 0 0 Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Vaccine development program contract expenses: Program service expenses 13,613,737. Management and general expenses 0. Fundraising expenses 0. Total expenses 13,613,737. Transcription/translation service: Program service expenses 34,521. Management and general expenses 244. Fundraising expenses 0. Total expenses 34,765. Consultants: Program service expenses 3,054,643. Management and general expenses 547,113. Fundraising expenses 67,617. Total expenses 3,669,373. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.